Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-200c (miR-200c) is a member of the miR-200 family and acts as a master regulator of the epithelial phenotype. It functions primarily as a tumor suppressor by inhibiting the expression of transcription factors such as ZEB1 and ZEB2, which are critical drivers of epithelial-to-mesenchymal transition (EMT). In aggressive cancers like triple-negative breast cancer (TNBC), miR-200c is often downregulated, and its restoration has been shown to suppress tumor growth and metastasis. Beyond its direct effects on tumor cells, miR-200c modulates the tumor microenvironment by inducing a cytokine profile (including the upregulation of GM-CSF) that promotes the polarization of macrophages toward an antitumor M1 phenotype. While currently in the preclinical stage of development, miR-200c mimics represent a potential RNA-based therapeutic strategy for treating metastatic and immune-suppressive cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-200c.